Iron Homeostasis-Regulated Adaptive Metabolism of PEGylated Ultrasmall Iron Oxide Nanoparticles

被引:0
作者
Wang, Ning [1 ]
Zhou, Dandan [1 ]
Xu, Keyang [1 ]
Kou, Dandan [1 ]
Chen, Can [1 ]
Li, Cang [1 ]
Ge, Jianxian [1 ]
Chen, Lei [1 ]
Zeng, Jianfeng [1 ]
Gao, Mingyuan [1 ,2 ,3 ]
机构
[1] Soochow Univ, Sch Radiol & Interdisciplinary Sci RAD X, Ctr Mol Imaging & Nucl Med, State Key Lab Radiat Med & Protect,Collaborat Inno, Suzhou 215123, Peoples R China
[2] Soochow Univ, Sch Life Sci, Suzhou 215123, Peoples R China
[3] Soochow Univ, Affiliated Hosp 2, Suzhou 215123, Peoples R China
基金
中国国家自然科学基金;
关键词
iron oxide nanoparticle; iron homeostasis; biodegradation; iron deficiency anemia; nanoparticlemetabolism; IN-VIVO; BLOOD-VOLUME; PHARMACOKINETICS; BIODEGRADATION; NANOTECHNOLOGY; MECHANISMS; FERRITIN; THERAPY; SYSTEM;
D O I
10.1021/acsnano.5c01399
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Iron oxide nanoparticles have become increasingly significant in the biomedical field due to their exceptional magnetic properties and biocompatibility. However, understanding their in vivo metabolism and transformation is crucial due to the potential biological effects they may induce. This study investigates the metabolic pathways of PEGylated ultrasmall iron oxide nanoparticles (PUSIONPs) in vivo, particularly under varying iron statuses and dosages. Employing a comprehensive analytical approach-including magnetic resonance imaging, elemental analysis, histological assessments, hematological analysis, and Western blot analysis-the biodistribution and transformation of PUSIONPs were mapped. The findings reveal significant differences in the metabolic fate of PUSIONPs between iron-sufficient and iron-deficient conditions, underscoring the pivotal role of iron homeostasis in regulating PUSIONPs biodegradation. In iron-deficient states, degradation and transformation were markedly accelerated, with the released iron rapidly incorporated into hemoglobin. Additionally, the liver and spleen exhibited different PUSIONPs metabolism rates due to their distinct physiological roles: the spleen, primarily responsible for iron recycling, facilitated faster degradation, while the liver, serving as an iron storage organ, showed slower degradation. Under iron deficiency, most degradation products were directed toward hemoglobin synthesis, whereas under normal conditions, the liver gradually metabolized the degradation products, and the spleen retained higher iron levels. Moreover, PUSIONPs degradation demonstrated dose dependency, with higher doses slowing degradation and reducing the utilization rate by the iron-deficient body. Comprehensive safety evaluations confirmed that PUSIONPs exhibit excellent biocompatibility across all doses, with no significant safety concerns. Compared to the clinically used intravenous iron supplement iron sucrose, PUSIONPs also demonstrated superior bioavailability and more effective iron supplementation. These findings provide critical insights into the interaction between iron oxide nanoparticles and iron metabolism, offering a foundation for future research and the broader application of PUSIONPs in biomedical contexts.
引用
收藏
页码:13381 / 13398
页数:18
相关论文
共 64 条
  • [1] In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
    Arami, Hamed
    Khandhar, Amit
    Liggitt, Denny
    Krishnan, Kannan M.
    [J]. CHEMICAL SOCIETY REVIEWS, 2015, 44 (23) : 8576 - 8607
  • [2] The available intravenous iron formulations: History, efficacy, and toxicology
    Auerbach, Michael
    Macdougall, Iain
    [J]. HEMODIALYSIS INTERNATIONAL, 2017, 21 : S83 - S92
  • [3] Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor
    Bentzen, L
    Vestergaard-Poulsen, P
    Nielsen, T
    Overgaard, J
    Bjornerud, A
    Briley-Sæbo, K
    Horsman, MR
    Ostergaard, L
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (04): : 1208 - 1215
  • [4] Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients:: a study using positron emission tomography
    Beshara, S
    Lundqvist, H
    Sundin, J
    Lubberink, M
    Tolmachev, V
    Valind, S
    Antoni, G
    Långström, B
    Danielson, BG
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) : 296 - 302
  • [5] Assessment of T1 and T*2 effects in vivo and ex vivo using iron oxide nanoparticles in steady state-dependence on blood volume and water exchange
    Bjornerud, A
    Johansson, LO
    Briley-Sæbo, K
    Ahlström, HK
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2002, 47 (03) : 461 - 471
  • [6] Pre-clinical results with Clariscan™ (NC100150 Injection);: experience from different disease models
    Bjornerud, A
    Johansson, LO
    Ahlström, HK
    [J]. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2001, 12 (2-3): : 99 - 103
  • [7] Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent
    Bourrinet, P
    Bengele, HH
    Bonnemain, B
    Dencausse, A
    Idee, JM
    Jacobs, PM
    Lewis, JM
    [J]. INVESTIGATIVE RADIOLOGY, 2006, 41 (03) : 313 - 324
  • [8] Brushmiller J. G., 1985, Q REVIEWOF BIOL, V60, P559, DOI [10.1086/414709, DOI 10.1086/414709]
  • [9] Iron deficiency
    Camaschella, Clara
    [J]. BLOOD, 2019, 133 (01) : 30 - 39
  • [10] Chaudhry H. S., 2024, MICROCYTIC HYPOCHROM